This promotional website has been developed, organised and funded by Boehringer Ingelheim.
The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.
Prescribing information for United Kingdom and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.
Focus on: Ramadan
It is important to conduct a pre-Ramadan assessment 6-8 weeks prior to Ramadan for adults with diabetes who wish to undertake fasting during this time1
Healthcare professional resources
A case-based approach to the practical management of type 2 diabetes during Ramadan and periods of fasting: A summary
Leaflet to share with your patients
Supporting your patients during Ramadan
Developed by Alia Gilani,
Pharmacist with a Special Interest in Diabetes and Cardiometabolic Disease
Alia Gilani is a specialist pharmacist whose interests lie in ethnic inequalities, diabetes and cardio-metabolic disease. She helped establish and run a bilingual medication review service in NHS Glasgow called the Minority Ethnic Long-Term (MELT) medicines service, which operated for over a decade and was recognised with awards at the local and national level.
Alia runs outreach clinics for South Asian individuals with diabetes and cardio-metabolic disease in various locations, including mosques and elderly care centres. She was a member of the diabetes working group for the South Asian Health Foundation for 13 years, and is now an appointed trustee of the foundation. She was the first pharmacist to become a member of the Primary Care Diabetes and Obesity Society committee, a position she held for 7 years, and she currently sits on the Diabetes UK Professional Conference organising committee.
References:
Watch the most recent webinar
Initiated and funded by Boehringer Ingelheim
PC-GB-110175 | July 2024
Prescribing information for the United Kingdom and Republic of Ireland.
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by OmniaMed Communications.
PC-GB-106628 V7 | November 2025
PC-GB-110742 V2 | November 2025
Quick questionnaire